SEARCH:   Advanced

Blood, 15 April 2007, Vol. 109, No. 8, pp. 3603-3606. Prepublished online as a Blood First Edition Paper on December 19, 2006; DOI 10.1182/blood-2006-05-024315. This Article Full Text (PDF) All Versions of this Article: blood-2006-05-024315v1 109/8/3603    most recent Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Rights and Permissions Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Lundqvist, A. Articles by Childs, R. Search for Related Content PubMed PubMed Citation Articles by Lundqvist, A. Articles by Childs, R. Social Bookmarking                   What's this?  Previous Article  |  Next Article  Submitted May 22, 2006 Accepted December 11, 2006 Reduction of GVHD and enhanced anti-tumor effects after adoptive infusion of alloreactive Ly49-mismatched NK-cells from MHC-matched donors Andreas Lundqvist*, J. Philip McCoy, Leigh Samsel, and Richard Childs Hematology Branch, National Heart Lung and Blood Institute, National Institutes of Health, Bethesda, MD, United States Flow Cytometry Core Facility, National Heart Lung and Blood Institute, National Institutes of Health, Bethesda, MD, United States * Corresponding author; email: lundqvia{at}nhlbi.nih.gov. We investigated if an infusion of alloreactive natural killer (NK)-cells would reduce GVHD and mediate anti-tumor effects in mice undergoing MHC-matched allogeneic stem cell transplantation (SCT). Balb/c mice bearing RENCA tumors underwent an allogeneic SCT from MHC-matched B10.d2 donors and were given a single infusion of either Ly49 ligand-matched, ligand-mismatched, or no donor NK-cells. Recipients of Ly49 ligand-mismatched NK-cells had a reduced incidence of GVHD (39% vs 100%; p<0.01), and prolonged survival (median 84 vs 39 days; p<0.01) compared to SCT recipients not receiving NK-cells. Recipients of Ly49 ligand-matched NK-cells had the same incidence of GVHD and similar survival compared to controls not receiving NK-cells. Pulmonary tumor burden was significantly (p<0.01) lower in recipients that received Ly49-mismatched or Ly49-matched NK-cells compared to recipients not receiving NK-cells. These data provide in-vivo evidence that a single infusion of alloreactive donor NK-cells reduces GVHD and mediates anti-tumor effects following MHC-matched allogeneic transplantation. CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this? This article has been cited by other articles: A. Lundqvist, H. Yokoyama, A. Smith, M. Berg, and R. Childs Bortezomib treatment and regulatory T-cell depletion enhance the antitumor effects of adoptively infused NK cells Blood, June 11, 2009; 113(24): 6120 - 6127. [Abstract] [Full Text] [PDF] S. Diermayr, H. Himmelreich, B. Durovic, A. Mathys-Schneeberger, U. Siegler, U. Langenkamp, J. Hofsteenge, A. Gratwohl, A. Tichelli, M. Paluszewska, et al. NKG2D ligand expression in AML increases in response to HDAC inhibitor valproic acid and contributes to allorecognition by NK-cell lines with single KIR-HLA class I specificities Blood, February 1, 2008; 111(3): 1428 - 1436. [Abstract] [Full Text] [PDF]

	Copyright © 2006 by American Society of Hematology         Online ISSN: 1528-0020